Metagenomi Therapeutics Ratios (2023-2026) | MGX

Ratios Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter) -160.98%-98.00%-150.56%-133.62%-225.36%-64.66%-181.34%-255.94%-604.34%-233.34%-238.21%-575.15%-1,846.88%
EBIT Margin (Quarter) -207.21%-158.45%-181.15%-162.88%-260.17%-84.28%-194.40%-214.51%-674.10%-246.53%-263.76%-623.04%-1,970.11%
EBITDA Margin (Quarter) -186.12%-116.29%-159.75%-153.50%-226.98%-53.61%-146.51%-253.05%-608.84%-236.78%-235.52%-578.85%-1,872.04%
Operating Margin (Quarter) -207.21%-158.45%-181.15%-162.88%-260.17%-84.28%-194.40%-214.51%-674.10%-246.53%-263.76%-623.04%-1,970.11%
Net Margin (Quarter) -186.36%-114.74%-160.32%-155.61%-225.36%-53.67%-163.04%-243.37%-606.71%-233.85%-235.51%-576.02%-1,847.68%
FCF Margin (Quarter) -273.34%-220.67%-244.39%-180.09%-275.70%-132.36%-224.26%-302.88%-560.46%-246.73%-245.80%-614.88%-1,698.72%
Efficiency
Assets Average (Quarter) 390.12M400.65M372.13M341.47M311.23M285.07M260.11M234.52M209.03M
Equity Average (Quarter) -96.28M-51.33M-67.85M70.02M272.53M262.60M245.31M223.76M204.24M187.14M168.52M148.19M
Invested Capital (Quarter) -90.01M-102.54M-0.12M-135.58M275.63M269.42M255.77M234.86M212.66M195.83M178.45M158.60M137.78M
Asset Utilization Ratio (Quarter) 0.120.140.150.150.150.120.120.110.11
Leverage & Solvency
Equity Ratio (Quarter) -0.370.660.700.710.720.710.720.720.720.70
Valuation
Enterprise Value (Quarter) -95.67M-51.65M-101.90M-271.18M-327.40M-299.92M-274.59M-248.31M-225.97M-204.99M-184.11M-160.80M-140.16M
Return Ratios
Return on Sales (Quarter) -0.01%-0.01%-0.02%-0.02%-0.02%-0.01%-0.02%-0.02%-0.06%-0.02%-0.02%-0.06%-0.18%
Return on Capital Employed (Quarter) -28.05%-25.44%-27.10%-29.23%-32.32%-36.46%-40.03%-45.38%-49.74%
Return on Invested Capital (Quarter) 0.01%-0.01%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%
Return on Assets (Quarter) 0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%
Return on Equity (Quarter) 0.01%-0.01%0.00%0.00%0.00%0.00%0.00%0.00%-0.01%-0.01%